Want to join the conversation?
$PRU said excluding the impact of its annual review and other market-driven and discrete items, adjusted operating EPS would have been $2.46, which is in line with expectations for 2Q16. Annualized return on equity on this same basis for 2Q16 at just over 13% was also consistent with the company's longer-term target.
Biodefense therapeutics firm $PIP announced an all-stock merger with biotech Altimmune. The respective boards of the two companies unanimously approved the merger.
$YHOO is reporting today after market close. Nobody cares about this stock.